文献速递慢性肾脏病

脂肪萎缩增加瑞士HIV阳性患者慢性肾脏病风险:LIPOKID研究

Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study.
PubMed 文献 · Kidney Int Rep · 2018-05-08

该前瞻性队列研究纳入瑞士HIV队列中5384例基线eGFR>60 ml/min/1.73 m²且随访超过3个月的患者,随访至2016年8月。1341例(24.9%)发生脂肪萎缩,252例(4.7%)达到主要终点(持续eGFR<60 ml/min/1.73 m²)。脂肪萎缩独立增加CKD风险(校正HR=2.37,95%CI 1.67-3.36,P<0.001),且该效应不通过肾毒性抗逆转录病毒药物介导。

要点

  • HIV阳性患者中临床诊断的脂肪萎缩与CKD发生独立相关。
  • 脂肪萎缩对CKD的影响不通过使用肾毒性抗逆转录病毒药物介导。
  • 需关注脂肪萎缩患者的肾功能监测。

核心结论

  • 在调整已知HIV和非HIV的CKD危险因素后,脂肪萎缩综合征仍独立与CKD发生相关。

研究设计与样本

  • 前瞻性队列研究(LIPOKID研究),纳入瑞士HIV队列研究2002年1月至2016年8月入组、基线eGFR>60 ml/min/1.73 m²且随访超过3个月的患者,共5384例。

主要发现

  • 中位随访72.3个月(SD±48.4)期间,1341例(24.9%)发生脂肪萎缩。
  • 252例(4.7%)达到主要终点,中位时间51.3个月(±SD 39.9个月)。
  • 单因素分析中脂肪萎缩显著增加eGFR<60 ml/min/1.73 m²风险(HR=2.72;95%CI 2.07-3.58;P<0.001)。
  • 多因素调整后风险仍显著升高(HR=2.37;95%CI 1.67-3.36;P<0.001)。
  • 脂肪萎缩对CKD的影响不通过使用肾毒性抗逆转录病毒药物介导。

关键数值与推荐

  • CKD定义为持续eGFR<60 ml/min/1.73 m²。
  • 脂肪萎缩为临床评估诊断。

临床怎么用

  • 对HIV阳性合并脂肪萎缩的患者,应加强肾功能监测以早期发现CKD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Antiretroviral therapy has improved the life expectancy of patients living with HIV. However, lipodystrophy syndrome (LD) remains prevalent, affecting mostly patients treated with first-generation antiretroviral drugs. This syndrome is characterized by changes in body fat distribution with or without associated metabolic changes. Here, we studied whether clinically evaluated LD is independently associated with chronic kidney disease (CKD) development (sustained estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m2) in HIV-positive patients. METHODS: We conducted a prospective cohort study (the LIPOKID Study) among all the patients from the Swiss HIV Cohort Study (SHCS) with an eGFR >60 ml/min per 1.73 m2 upon their entry into the cohort with more than 3 months of follow-up from January 2002 to August 2016. Cox regression models were used to estimate the association between LD and CKD development. RESULTS: Among the 5384 patients included, 1341 (24.9%) developed LD during the follow-up. The mean follow-up time was 72.3 months (SD ±48.4). In total, 252 patients (4.7%) reached the primary endpoint after a median time of 51.3 months (±SD 39.9 months) from inclusion. A diagnosis of LD significantly increased the risk of an eGFR on univariate analysis (hazard ratio [HR] = 2.72; 95% confidence interval [95% CI] = 2.07-3.58; P < 0.001) and remained significantly higher after adjustment for known HIV and non-HIV risk factors for CKD (HR = 2.37; 95% CI = 1.67-3.36; P < 0.001). The effect of LD on CKD was not mediated through the use of nephrotoxic antiretroviral drugs. CONCLUSION: Lipodystrophy syndrome is independently associated with CKD after adjustment for previously reported risk factors.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bouatou Y, Gayet Ageron A, Bernasconi E, et al. Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. Kidney Int Rep. 2018. PMID: 30197975. doi:10.1016/j.ekir.2018.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。